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In this study, the evolution of sensitization to peanut allergen molecules from early childhood to 81 adolescence was investigated for the first time. 82
We used a random subset of 778 children from the Swedish BAMSE birth cohort (N=4089) 5 where 83 complete relevant questionnaire data from baseline (2 months), 1, 2, 4, 8 and 16 years and blood 84 samples from 4, 8 and 16 years were available. For some of the analyses, this population-based study 85 group was enriched with additional 84 peanut extract-sensitized children (at 4, 8 and/or 16 years) from 86 the same cohort. Thus, our peanut-enriched study group included 862 children (778 from the population-87 based study group enriched with 84 peanut sensitized children) ( Figure E1 ). Serum samples were 88 analyzed for IgE antibodies to peanut extract, and at 8 years of age also to Ara h 2, by ImmunoCAP 89 (Thermo Fisher AB, Uppsala, Sweden) and for peanut allergen molecules (Ara h 1, h 2, h 3, h 6, h 8 and h 90 9) using a modified allergen chip based on ISAC technology (Thermo Fisher) 5 In the population-based study group, the frequencies of sensitization to storage proteins showed little 96 change from 4 to 16 years, but sensitization to the birch pollen homologous allergen molecule Ara h 8 97 increased at each time point ( Figures 1A and 1B) . Any reported systemic symptom to peanut in 98 combination with peanut storage protein sensitization increased from 1.4% at 8 years to 3.0% at 16 Table E1 ). The prevalence rates and trajectories, i.e. onset, persistence and transition of 100 IgE reactivity, as well as IgE-levels to peanut extract and the different peanut allergen molecules are 101 displayed in Figures 1A and 1B . 102
Due to the substantial overlap of sensitization to the peanut storage proteins ( Figures E2 and E3 ), no 103 multivariate logistic regression estimates for IgE reactivity to each storage protein in relation to allergic 104 symptoms to peanut could be performed. Of the 54 Ara h 2-sensitized children at 16 years in the peanut-105 enriched study group, 45 (83%) were already sensitized at 4 years and 49 (91%) reported symptoms to 106 peanut at 16 years. Only one participant had de novo Ara h 2 sensitization (0.8 ISU-E) after 8 years (data 107 not shown). The high rate of storage protein sensitization at 4 years among children developing peanut 108 allergy during the first 16 years of life raises the important question of prevention. 109
In children with both peanut and birch pollen sensitization, one fraction was mono-sensitized to Ara h 8 110 ( Figure 2 ). These children reported no peanut symptoms or only oral allergy syndrome (OAS) at 16 years 111 of age. We have previously reported that sensitization to Ara h 8 is associated with mild OAS or peanut 112 tolerance 6 . Interestingly in this study, most children with onset of peanut sensitization after 4 years had 113 IgE reactivity to Ara h 8 only and not to the storage peanut proteins, and were mostly asymptomatic or 114 without report of any systemic symptoms 4, 6 . Another fraction of children was sensitized to Ara h 2 115 (regardless co-sensitization to Ara h 8). At 16 years, peanut symptoms at exposure were reported in 91% 116 of these Ara h 2 sensitized participants. 117
The predicted longitudinal likelihood of reporting peanut allergy at 16 years in the peanut-enriched study 118 group (n=862) was plotted in relation to IgE-levels to Ara h 2 ( Figure E4A , incident symptoms Figure E4B ), 119 peanut extract ( Figure E4C ) as well as to the number of sensitizing peanut allergen molecules 4 years of 120 age ( Figure E4D ). An IgE-level of >2.0 ISU-E to Ara h 2, >15.5 kU A /L to peanut extract or IgE reactivity 121 (≥0.3 ISU-E) to at least 4 peanut allergen molecules at 4 years of age corresponded to a 95% likelihood of 122 reporting peanut symptoms 12 years later. 123
Due to the large number of children investigated in the BAMSE cohort it was not possible to verify 124 peanut symptoms with the double-blind placebo-controlled food challenge (DBPCFC). However, the 125 calculated longitudinal peanut extract-specific IgE level at 4 years (15.5 kU A /L) with a 95% likelihood of 126 peanut symptoms at 16 years is very similar to the one reported in a cross-sectional clinical study by 127
Sampson and colleagues (15 kU A /L) where DBPCFC were included 7 . Several previous DBPCFC studies 128 M A N U S C R I P T
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Asarnoj et al 8 demonstrate that even low Ara h 2 IgE-levels are associated with peanut allergy in almost all cases, 129 which was shown in our study as well although most other studies measured Ara h 2 IgE with the 130
ImmunoCAP method 2, 7, 8 . As the results in ISAC are semiquantitative and may be influenced by blocking 131
IgG antibodies, they cannot simply be transferred to ImmunoCAP. We made a comparison with 132
ImmunoCAP values at 8 years of age and in the BAMSE cohort, an Ara h 2 level of 2.0 ISU-E in microarray 133 corresponded to 4.1 kU/L in ImmunoCAP (data not shown). 134
135
In summary, our study is the first to examine the onset and persistence of IgE sensitization to peanut 136 allergen molecules in relation to peanut symptoms from preschool age to adolescence. We identified 137 two distinct phenotypes in the development of peanut allergy from childhood to adolescence. One 138 phenotype develops early in life and is related to Ara h 2 sensitization and risk of systemic reactions after 139 peanut exposure. Children with this phenotype rarely outgrow their symptoms. The second phenotype, 140 which starts later in childhood, is related to Ara h 8 sensitization and non-systemic reactions after peanut 141 ingestion. Furthermore, we show that in preschool children, Ara h 2 sensitization or polysensitization to 142 peanut storage proteins are superior in predicting peanut allergy in adolescence compared to peanut 143 extract sensitization. We suggest that measuring IgE to peanut allergen molecules may help clinicians 144 improve the diagnosis and prognosis of peanut allergy. 145
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In 1699 children, 42% of the original cohort, blood samples were available from all three clinical follow 7 ups (4, 8 and 16 years). In this group of children, a random subset of 800 was collected of which 778 had 8 complete data on peanut allergy at 16 years and sufficient serum volumes for analysis, denoted as the 9 population-based study group. 10
For some of the analyses, this population-based study group was enriched with all remaining peanut 11 extract-sensitized children (measured with ImmunoCAP (f13) at 4, 8 and/or 16 years of age) among the 12 group of 1699. This resulted in 84 additional children for which complete peanut symptom data at 16 13 years of age and sufficient volume of serum for analysis were available. Thus, our peanut-enriched study 14 group included 862 children (778 from the population-based study group enriched with 84 peanut 15 sensitized children) ( Figure E1) . 16
Permission for the study was obtained from the Regional Ethical Review board at Karolinska Institutet at 17 each follow up and parents of participating children gave their informed consent. At 16 years, the 18 participating teens gave their separate consent. 19
Definition of symptoms 20
All data on peanut symptoms were collected through questionnaires answered by the children's parents 21 at 1, 2, 4, 8 and 16 years. Specific organ symptoms to peanut were asked at 8 and 16 years. "Itching in mouth", "Trouble breathing", "Vomiting or diarrhea", "Eczema", "Nettle rash", "Avoided 27 foodstuff because of previous adverse reaction". 28
Peanut allergy at 16 years: Any of the following symptoms to peanut indicated: "Difficulty breathing, 29 asthma, cough", "Itchy nose, stuffy nose, runny nose, itchy eyes", "Nettle rash covering most of the 30 body", "Nettle rash that covered less", "Vomiting, stomach pain", "Swelling in face, eyelids, lips", 31 "Hoarseness, indistinct speech", "Swollen feeling in mouth, throat", "Itch in mouth, throat, ears", 32 "Pronounced fatigue, decreased awareness" and "Unconsciousness". 33
Individuals with a positive answer to "Itch in mouth, throat, ears" and negative to all other symptoms 34 were regarded as having local symptoms only (Oral Allergy Syndrome=OAS). Systemic peanut symptoms 35
were defined as at least one positive answer to "Difficulty of breathing, asthma, cough" or "Nettle rash 36 covering most of the body" or "Vomiting, stomach pain" or "Swelling in face, eyelids, lips" or 37 "Hoarseness, indistinct speech" or "Pronounced fatigue, decreased awareness" or "Unconsciousness". 38
Allergen-specific IgE measurement 39
Serum samples were analyzed with ImmunoCAP (Thermo Fisher AB, Uppsala, Sweden) for allergen-40 specific IgE antibodies to peanut extract (f13) and at 8 years of age also to Ara h 2. A positive test was 41 defined as ≥0.35 kU A /L. An IgE antibody level >100 kU A /L was given the value of 101 kU A /L in statistical 42 evaluations and an IgE level <0.35 was set to 0. 43 IgE reactivity to the peanut allergen molecules (Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8 and Ara h 9) was 44 analyzed using a modified allergen chip based on ISAC technology (Thermo Fisher) 
Figure E2.
Ara h 2/Ara h 6 sensitization overlap at 4, 8 and 16 years of age. Median IgE levels (ISU-E) in the sensitization subgroups. N=862 (peanut-enriched study group) Figure E3 . Ara h 1/Ara h 2/Ara h 3 sensitization overlap at 4, 8 and 16 years of age. Median IgE levels (ISU-E) in the sensitization subgroups. N=862 (peanut-enriched study group) Figure E4 . Likelihood of reporting symptoms to peanut at 16 years of age in relation to A) Ara h 2 IgE level at 4 years of age (ISU-E), B) Ara h 2 IgE level at 4 years of age (ISU-E) (incident symptoms), C) peanut extract IgE level at 4 years of age (kU A /L) or D) number of sensitizing peanut allergen molecules (Ara h 8 excluded)/ peanut extract sensitization at 4 years of age. N=862 (peanut-enriched study group)
